[Skip to Content]
[Skip to Content Landing]
Views 6,979
Citations 0
From The Medical Letter on Drugs and Therapeutics
August 6, 2019

Omadacycline (Nuzyra) A New Tetracycline Antibiotic

JAMA. 2019;322(5):457-458. doi:10.1001/jama.2019.8199

The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults (Table 1).

Omadacycline has a broad spectrum of activity that includes gram-positive, gram-negative, atypical, and anaerobic pathogens (see CAP and ABSSSIs sections for specific clinical activity). It has been shown to have in vitro activity against some drug-resistant pathogens including penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci (VRE), beta-lactamase-positive Haemophilus influenzae, Acinetobacter species, and non-ceftazidime-susceptible and non-imipenem-susceptible Enterobacteriaceae, but it is not active against Pseudomonas, Proteus, Morganella, or Providencia species.1-3